Retatrutide Guide & Protocols

Retatrutide is the compound most of this audience is watching right now. Below is the weekly escalation pattern most commonly described, how it's cycled and stacked, and how it compares to tirzepatide if you're weighing the two.

Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target dose you're working with.

What it is

Retatrutide is a synthetic peptide that activates three separate metabolic hormone receptors at once: GIP, GLP-1, and glucagon. That third pathway, glucagon, is the piece that sets it apart from compounds that only work through one or two of those receptors, and it's proposed to add its own energy-expenditure and fat-burning effect on top of the appetite and blood-sugar effects the other two pathways drive. It's sold as a research chemical, not an FDA-approved drug or supplement, and there's no pharmacy or prescription channel for it. Research-grade material sold by peptide vendors isn't manufactured to pharmaceutical standards, and purity and concentration accuracy vary by source.

What people use it for

Retatrutide shows up almost entirely in one conversation: body weight and metabolic research. The reported weight reductions in the studied dose range are among the largest reported for any compound in this category, which is the main reason it gets so much attention. A secondary interest sits in liver fat and general metabolic markers, since the same mechanism that drives weight loss also appears to affect fat stored in the liver and measures like triglycerides, blood pressure, and waist circumference.

Formulations

Retatrutide ships as a lyophilized (freeze-dried) powder that needs reconstitution before use. Vendors most commonly sell 10, 20, and 30 mg vials, individually or as a bulk kit of 10 vials, which is usually the cheaper way to buy in for a maintained, months-long schedule. There's no oral or nasal commercial formulation, so subcutaneous injection of the reconstituted solution is the only route people run.

Dosing protocols

There's no single settled weekly amount for retatrutide. What circulates is an escalation pattern that mirrors how the compound itself was originally dosed, starting low and stepping up every few weeks toward a target amount, rather than a number pulled from nowhere.

See the Retatrutide research notes for more background before reading the dosing itself.

Standard escalation

The most commonly referenced pattern. Starting weekly amount: 1 to 2 mg. Route: subcutaneous injection. Escalation: stepped up roughly every 4 weeks. Target maintenance amount: most often 4, 8, or 12 mg weekly, held once reached.

Slower escalation

A gentler, less commonly used variant. Starting weekly amount: 2 mg. Route: subcutaneous injection. Escalation: smaller steps, roughly every 4 weeks, on the way to the same target amounts above. Commonly described as easier to tolerate on the way up, at the cost of taking longer to reach the target.

Amount total, for planning your vial purchase: a maintained weekly amount of 8 to 12 mg, run for a year (52 weeks), works out to roughly 415 to 625 mg total, which is a lot of 10, 20, or 30 mg vials. That total is part of why a bulk kit of 10 vials is commonly the better buy over single vials for anyone running a maintained schedule rather than a short trial. Compare vendors on price per milligram against that total rather than against the price of a single vial.

How much to reconstitute at once: a reconstituted vial is generally good for about 28 days refrigerated, so the amount to mix at one time is whatever four weeks of the current step actually uses, not the whole vial. Early in escalation, four weeks at 1 to 2 mg weekly only draws 4 to 8 mg, which leaves most of a 10 mg vial unused once the 28-day window closes, never mind a 20 or 30 mg vial or a bulk-kit vial. Once a maintenance amount of 8 to 12 mg weekly is reached, four weeks draws 32 to 48 mg, which lines up much closer to a 30 mg vial. See how much to reconstitute at once for the general math.

Cycling guidelines

Retatrutide doesn't have a defined on-then-off cycling convention the way some shorter-course research peptides do. What's described instead is a single, sustained escalation to a maintenance weekly amount, continued for as long as someone is actively pursuing the effect, commonly discussed in stretches of many months to a year or more rather than a matter of weeks. We couldn't find a source for a specific rest-period convention, which is worth knowing before assuming one exists.

Where stopping comes up, it's more often described as a gradual step down in weekly amount rather than an abrupt stop, though we found no source establishing a specific taper schedule either.

Signs a course is commonly stopped or reconsidered:

• Severe or persistent abdominal pain, particularly if it radiates to the back
• Signs of a gallbladder problem, such as pain in the upper right abdomen or yellowing of the skin or eyes
• A resting heart rate that stays elevated rather than settling after a dose step
• Digestive symptoms severe enough to affect eating or hydration day to day

Stacking

Most commonly paired stack: Retatrutide with CJC-1295 and Ipamorelin.

Rationale: these two peptides drive growth hormone release through separate pathways, and the combination is discussed specifically for preserving lean mass, sleep quality, and recovery during a significant, sustained calorie deficit, which is exactly what a retatrutide course tends to create.

Protocol as run: CJC-1295 (commonly the no-DAC, faster-clearing version when paired with Ipamorelin) and Ipamorelin dosed daily, most often before sleep, run alongside retatrutide's weekly schedule rather than matched to it.

Why it's paired: the two are addressing different problems. Retatrutide is working at the appetite and receptor level; the GH pair is aimed at what a hard, sustained deficit tends to cost you, mainly muscle.

Lighter stacks: BPC-157 and TB-500 together show up as a gut-and-tissue-support pairing, since the digestive side effects common early in a retatrutide course overlap with what BPC-157 is studied for. MOTS-c shows up as a cellular-energy pairing, addressing fuel efficiency at the mitochondrial level rather than the hormonal level retatrutide works through. Both are rationale plus a loosely matched schedule, not protocols with any dedicated combination data.

Combinations to approach carefully: cagrilintide is the one that comes up most, since it would add a fourth active pathway on top of retatrutide's three, and no combination has been studied. Stacking a fourth pathway onto a compound that's already the most mechanistically complex thing on this site is a bigger leap than adding it to a single-pathway compound, and isn't something we found a safety rationale for anywhere.

Expected results timeline

Early weeks: this is mostly an adjustment period. Digestive symptoms are the most noticeable thing during this stretch, especially right after each step up in weekly amount, and appetite changes are usually apparent well before any real weight change is.

Months in: this is where the effects most people are tracking for start showing up, appetite, weight, and the metabolic markers that move alongside it. The higher the weekly amount someone reaches, the larger the average effect tends to be, though individual variation is wide.

Extended, continued use: the largest cumulative changes, in body composition, waist measurement, and metabolic markers, are described as building over many months to roughly a year or more of sustained use at a maintained weekly amount, not something that shows up quickly.

What to expect realistically: average reductions at the higher end of the studied weekly range have been large enough to be among the biggest numbers reported for any compound in this category, but averages hide a wide spread between individuals. What happens to appetite and weight after stopping isn't something this compound has its own settled answer for yet, since it's still relatively early for it compared to older compounds in the same category.

Administration technique

1. The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for the target weekly amount.
2. The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptide.
3. The calculated volume is drawn into an insulin syringe or similar fine-gauge syringe.
4. A subcutaneous site is chosen, commonly the abdomen or the front of the thigh, with sites rotated week to week.
5. The skin is pinched and the injection given at roughly a 45-degree angle, held for a few seconds before withdrawal.
6. Each weekly injection is commonly logged by date, amount, and site, which matters more here than for a short course, since a maintained schedule can run for many months.

Side effects and safety

Common: nausea is the most consistently reported effect, and it climbs with weekly amount, most noticeable right after a step up. Diarrhea, constipation, and vomiting follow a similar pattern, more common at higher weekly amounts.

Less common: a modest, dose-related rise in resting heart rate has been reported during a course, and it's one of the things researchers watch given how the glucagon piece of the mechanism works. Mild injection-site irritation is also reported.

Stopping due to side effects: people leaving a course because the digestive effects are hard to tolerate becomes more common as the weekly amount goes up.

What we don't know: there's no long, complete real-world safety picture for retatrutide yet, since it's still relatively early for this compound. Treat anything beyond the studied window as an open question, not a settled one.

Contraindications: the same class-level cautions applied to other compounds that work through the GLP-1 pathway are commonly extended to retatrutide too, a personal or family history of a rare thyroid tumor type, and a personal history of pancreatitis, based on the caution used across this wider category of compound rather than long-run data specific to retatrutide itself. Pregnancy, breastfeeding, and use in minors all have no data behind them and should be avoided.

Drug interactions: this category of compound is understood to slow how quickly the stomach empties, so it's reasonable to expect it could affect how quickly anything else taken by mouth around the same time gets absorbed. That's a mechanism-based caution rather than something specifically tested for retatrutide, and none have been formally characterized for it.

Retatrutide vs. Tirzepatide

If you're weighing retatrutide against something else, tirzepatide is the compound people actually cross-shop it against, since retatrutide is often described as tirzepatide's successor.

Choose retatrutide if: the largest reported average effect size in this category is what you're after, and you're comfortable with a compound that has a shorter track record and no approved status.

Choose tirzepatide if: you'd rather work with a compound that has an approved, prescribable version with a longer clinical history behind it.

See the tirzepatide vs. retatrutide cost comparison for how the two actually price out per milligram, and the Tirzepatide research notes for pricing and vendor info.

Storage and handling

Lyophilized powder: refrigerate at 2 to 8°C for near-term use. Kept frozen instead, the unreconstituted powder is commonly described as stable for considerably longer, which is part of why a bulk kit makes practical sense for a maintained, months-long schedule rather than something that has to be used up quickly. Protect from light. Lot-specific stability should come from the vendor's certificate of analysis, not a general rule.

Reconstituted solution: refrigerate, and plan to use it within the window your vendor specifies, generally within 28 days once water has been added. That 28-day figure comes from the same compounding-pharmacy standard used industry-wide for a bacteriostatic-water solution, not from a retatrutide-specific study. See how much to reconstitute at once before buying a larger vial or bulk kit than the 28-day window can realistically use. Avoid repeated freeze-thaw cycles.

Signs of degradation:

• Cloudiness or visible particles in a solution that was previously clear
• Discoloration of the powder or reconstituted liquid
• A previously reliable appetite or weight effect that unexpectedly stops showing up at an unchanged weekly amount, though this is a soft signal at best

FAQ

Retatrutide or tirzepatide, which one do I actually want? If an approved, prescribable option with a longer track record matters most, tirzepatide. If the largest reported average effect size in this category is the priority, retatrutide.

How is it typically escalated? Most commonly starting around 1 to 2 mg weekly and stepping up roughly every 4 weeks toward a target weekly amount, though the exact steps described vary by source.

How long do people run it? Commonly many months to a year or more at a maintained weekly amount, rather than a short, defined course.

Can I take it orally? There's no commercial oral formulation. What circulates is injectable.

Is it safe to combine with the GH pair, CJC-1295 and Ipamorelin? No dedicated combination data exists. People run them together based on the different problems each addresses, not on tested safety.

Does the weekly amount affect side effects? Yes, digestive side effects and the rate of people stopping altogether both track upward with weekly amount.

Is there a thyroid or pancreatitis risk? The same caution used across this class of compound is commonly extended to retatrutide, based on the class rather than long-run data specific to it. See Side effects and safety above.

How is it stored? Refrigerated as a powder, refrigerated and used within about 28 days once reconstituted.

What's the difference between the vial sizes? Only the concentration and how many vials your weekly schedule requires over time; 10, 20, and 30 mg are the common sizes, and the reconstitution calculator handles the arithmetic either way.

Is a bulk kit worth it? A kit of 10 vials is commonly described as the cheaper way to buy in per milligram, and it makes sense for anyone running a maintained schedule over many months rather than testing the water with one vial.

Bottom line

Key dosing takeaways:

• Escalating from around 1 to 2 mg weekly up toward a maintenance amount, most often 4, 8, or 12 mg, over roughly 3 to 4 months, is the shape people actually run
• That escalation shape traces directly back to how the compound's own dosing was structured, unlike some research peptides where the popular number has no traceable origin
• Digestive side effects and the rate of people stopping altogether both climb with weekly amount, which is the main tradeoff against the larger average effect size at the higher end

Best practices:

• Comparing vendors by total milligrams over a realistic multi-month course, not by vial count, is where the real price differences show up
• Logging each weekly injection keeps a maintained schedule from relying on memory over many months
• A gradual, rather than abrupt, approach to any dose change is what's most commonly described, even without a formally established taper schedule

Works best for people who:

• Are prioritizing the largest reported average effect size in this category over a longer track record
• Are comfortable with a compound that has no approved status and a shorter real-world history than its predecessors
• Can tolerate, or are prepared to manage, dose-dependent digestive side effects during escalation